Abstract:AIM: To explore whether there is a synergisticeffect between evodiamine (EVO) and RO3306,a specific cyclin-dependent kinase 1 (CDK1)inhibitor, on the proliferation and apoptosis ofmurine colon cancer CT26 cells.METHODS: The inhibitory effect of EVO on the proliferation of CT26 cells was determined by MTT assay to calculate IC50 at 24 h and the time required for the induction of irreversible apoptosis. The inhibitory effect of combination treatment with EVO and RO3306 either in a simultaneous or sequential way (pretreatment withEVO for 24 h followed by addition of RO3306 for another 6 h) on cell proliferation was also detected. CT26 cells were divided into six groups:control group, 2 mg/L EVO group, 4 mg/L EVO group, 15 mg/L RO3306 group, 2 mg/L EVO + 15 mg/L RO3306 group, and 4 mg/L EVO + 15 mg/L RO3306 group. Colony-forming assay and flow cytometry (FCM) assay were used to detect the effect of these treatments on cell proliferang, tion and apoptosis. q-value analysis was used to estimate the synergistic effect of evodiamine and RO3306. A q value of ≥1.15 indicates synergism.RESULTS: Treatment with EVO alone for 24 h had a significant inhibitory effect on CT26 cell proliferation, and IC50 was around 10.8 mg/L. The time required for the induction of irreversible apoptosis was 24 h. Combination treatment with EVO and RO3306 in a sequential way resulted in the rates of reduced proliferation of 22.0 ± 4.4%, 30.4 ± 3.2%, 12.3 ± 4.8%, 48.0 ± 3.2%, and 62.2±2.2% in each treatment group. The q values of the two sequential treatment groups were 1.52 and 1.60, while those of simultaneoustreatment groups were 0.68 and 0.72, respective-ly. Colony-forming assay showed the reduced rates of colony formation were 9.7 ± 5.8%, 38.9 ± 3.8%, 10.8 ± 3.7%, 29.8 ± 10.7%, and 68.3 ± 12.7% in each treatment group. The q values of the two sequential treatment groups were 1.41 and 1.47. FCM assay showed that the apoptotic rates were 5.5±1.1%, 18.3 ± 1.9%, 25.6 ± 1.5%, 9.2 ± 1.1%, 39.1 ± 9.8%, and 54.6 ± 1.2% in each group (q > 1.15).CONCLUSION: The time required for induction of irreversible apoptosis of CT26 cells by EVO isaround 24 h and the inhibitory effect was dosedependent. EVO exhibited a significant synergistic inhibitory effect with RO3306 on CT26 cellbut not in a simultaneous treatment manner.

Synergistic killing effect of evodiamine combined with RO3306,a CDK1 inhibitor,on murine colon cancer CT26cells

[Effect of Evn-50 on Cell Growth and Apoptosis in Tamoxifen-Resistance Human Breast Cancer Cell Line MCF-7/TAM-R].

Evodiamine Inhibits Proliferation and Induces Apoptosis in Gastric Cancer Cells.

Evodiamine induces apoptosis and enhances apoptotic effects of erlotinib in wild-type EGFR NSCLC cells via S6K1-mediated Mcl-1 inhibition

The Synergistic Anti-tumor Effects of Evodiamine based on Animal Model Experiments: A Systematic Review and Meta-analysis

[Specific Killing Effects of Combination of Recombinant Adenovirus Containing Double Suicide Gene Driven by KDR Promoter and Survivin Antisense Oligonucleotide on Colorectal Cancer Cells and Vascular Endothelial Cells].

Evodiamine inhibits malignant progression of ovarian cancer cells by regulating lncRNA‐NEAT1/miR‐152‐3p/CDK19 axis

Evodiamine inhibits the proliferation of human osteosarcoma cells by blocking PI3K/Akt signaling

Synergistic Inhibition of Sunitinib and Ethaselen Against Human Colorectal Cancer Cells Proliferation.

Evodiamine Suppresses ABCG2 Mediated Drug Resistance by Inhibiting p50/p65 NF-κB Pathway in Colorectal Cancer

Synergetic Inhibition of Human Colorectal Cancer Cells by Combining Polyyne-Enriched Fraction from Oplopanax Elatus and Irinotecan

[Synergistic Effect of Rapamycin (RPM) and PD98059 on Cell Cycle and Mtor Signal Transduction in Human Colorectal Cancer Cells].

DNA Methyltransferase Inhibitor and Rapamycin Synergistically Modulate Cell Cycle and Mammalian Target of Rapamycin Signaling Pathway for Human Colorectal Cancer Cells

Combined treatment with Aronia berry extract and oligomeric proanthocyanidins exhibit a synergistic anticancer efficacy through LMNB1-AKT signaling pathways in colorectal cancer

Influence of Oridonin Combined with Melphalan on Proliferation and Apoptosis of Human Myeloma RPMI8226 Cells

In Vitro Additive Antitumor Effects of Dimethoxycurcumin and 5‐fluorouracil in Colon Cancer Cells

Effects of Tamoxifen Combining with Everolimus and PI3K Inhibitor on ER-positive Breast Cancers

Synergistic inhibition effects of gemcitabine and octreotide on prostate cancer cell line PC-3

Study of synergistic mechanism in the combination ofberberine and evodiamine from the perspective of miRNA

Antitumor Effects of Evodiamine in Mice Model Experiments: A Systematic Review and Meta-Analysis

Efficacy and mechanism of combination of oxaliplatin with PKM2 knockdown in colorectal cancer